Related Experiment Videos
Soft tissue sarcoma in children: prognosis and management
Ewa Koscielniak1, Mary Morgan, Jörn Treuner
1Olga Hospital, Pediatric Center, Bismarckstrasse 8, Stuttgart 50-176, Germany. e.koscielniak@olgahospital.de
Paediatric Drugs
|January 31, 2002
Summary
Pediatric soft tissue sarcomas (STS) are diverse cancers requiring specialized care. Advances in genetic classification and multicenter studies have improved treatment strategies and survival rates for these childhood tumors.
Area of Science:
- Pediatric Oncology
- Medical Genetics
- Cancer Therapy
Background:
- Soft tissue sarcomas (STS) constitute approximately 7% of childhood malignant neoplasms.
- The heterogeneity of STS presents diagnostic and therapeutic challenges, necessitating expert management in specialized centers.
- Significant progress in STS diagnosis and classification has been achieved through the identification of specific genetic alterations in subtypes like rhabdomyosarcoma, synovial sarcoma, and Ewing's tumor family.
Purpose of the Study:
- To review advancements in the diagnosis, classification, and treatment of pediatric soft tissue sarcomas.
- To highlight the impact of multicenter studies on improving therapeutic strategies and patient prognosis.
- To summarize effective chemotherapeutic agents and radiotherapy recommendations for STS.
Main Methods:
- Analysis of data from large multicenter STS studies (e.g., North-American Intergroup Rhabdomyosarcoma Study, German CWS, SIOP).
- Identification of prognostic variables and establishment of criteria for multimodal treatment approaches.
- Evaluation of chemotherapy drugs (dactinomycin, vincristine, cyclophosphamide, ifosfamide, doxorubicin) and radiotherapy protocols.
Main Results:
- Multicenter studies have led to improved treatment strategies and prognosis for pediatric STS over the past 30 years.
- Event-free survival rates for STS range from 50% to 80% with combined chemotherapy and local therapy.
- Metastatic disease at diagnosis, particularly in older children or with bone/marrow involvement, is associated with a poor prognosis (20-30% 5-year survival).
Conclusions:
- Pediatric soft tissue sarcomas require specialized care due to their heterogeneity and complexity.
- Advances in genetic classification and multimodal treatment strategies have significantly improved outcomes.
- Further research, including controlled studies, is needed to clarify the role of high-dose chemotherapy with stem cell rescue for poor-prognosis STS.